Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MACC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MACC1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified (ZU5 and SH3 domains). |
View MACC1 Products |
| Gene Delivery | MACC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MACC1 Products |
| Benchmark Ab | Anti-MACC1 Antibody Recombinant positive control. |
View MACC1 Products |
| Validator | MACC1 siRNA Set For knockdown verification. |
View MACC1 Products |
| Related Target A | MET Primary downstream effector kinase in the MACC1 signaling axis. |
View MET Products |
| Related Target B | HGF Ligand for the MET receptor, synergizing with MACC1-driven metastasis. |
View HGF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PPI Screening (SH3 domain proteins) | High-purity recombinant MACC1 with intact ZU5 and SH3 domains, strictly verified by mass spec. |
| Intracellular Targeting | HEK293 Expressed proteins and Lentivirus for physiologically relevant cell-based assays. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks and target validation. |
Live MACC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MACC1 therapeutics is intensifying as its role as a master regulator of the HGF/c-Met pathway in colorectal cancer metastasis becomes clearer. Because MACC1 is an intracellular target lacking intrinsic enzymatic activity, major players are shifting focus from traditional modalities to Protein-Protein Interaction (PPI) inhibitors, PROTACs, and RNAi. As first-generation approaches advance in preclinical models, the next wave of R&D is targeting the specific disruption of MACC1's SH3 domain interactions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Mol (PPI) | Preclinical Biotechs | Colorectal Cancer (CRC) | Binding Assay (Need high-purity SH3 domain proteins) |
| PROTACs | Academic / Discovery | Metastatic Solid Tumors | Degradation Assay (Need Lentivirus for stable cell lines) |
| RNAi / ASO | Discovery Stage | Refractory CRC | Knockdown Validation (Need validated siRNA sets) |